CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform
Condition: Non-Small Cell Lung Cancer
Sponsor: Elephas Biosciences Corporation
Full Title
Protocol ELEP-2022-CYBRID-01: Observational lung trial to collect tissue to train and validate a live tumor diagnostic platform
Study Treatment
The study includes one scheduled on-site visit for baseline enrollment. Biopsy(ies) will be collected from all enrolled subjects. The biopsy should be collected as an additional pass(es) during a standard of care core needle biopsy.
Eligibility/Info
- Patients with suspected metastatic non-small cell lung cancer that will be undergoing a core biopsy at the Lake Success Medical Oncology office.
Elephas will train and validate its cancer diagnostic platform for prediction of drug response, with a focus on the checkpoint inhibitor pembrolizumab (Keytruda).
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
